Investing.com··Jeffrey Neal JohnsonLilly Bets $10B on AI and Neuroscience to Diversify Beyond GLP-1 Boom
Eli Lilly commits $10B to AI drug discovery partnership and sleep disorders acquisition, diversifying beyond its GLP-1 franchise.
LLYCNTArevenue diversificationartificial intelligence